Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.

Chiozzini C, Olivetta E, Sanchez M, Arenaccio C, Ferrantelli F, Leone P, Federico M.

J Mol Med (Berl). 2019 Jun 3. doi: 10.1007/s00109-019-01797-7. [Epub ahead of print]

PMID:
31161312
2.

DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors.

Ferrantelli F, Manfredi F, Chiozzini C, Anticoli S, Olivetta E, Arenaccio C, Federico M.

Mol Biotechnol. 2018 Nov;60(11):773-782. doi: 10.1007/s12033-018-0114-3.

PMID:
30167966
3.

Exosomes in Therapy: Engineering, Pharmacokinetics and Future Applications.

Arenaccio C, Chiozzini C, Ferrantelli F, Leone P, Olivetta E, Federico M.

Curr Drug Targets. 2019;20(1):87-95. doi: 10.2174/1389450119666180521100409.

PMID:
29779478
4.

Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.

Anticoli S, Aricò E, Arenaccio C, Manfredi F, Chiozzini C, Olivetta E, Ferrantelli F, Lattanzi L, D'Urso MT, Proietti E, Federico M.

J Mol Med (Berl). 2018 Feb;96(2):211-221. doi: 10.1007/s00109-017-1617-2. Epub 2017 Dec 27.

PMID:
29282521
5.

An Exosome-Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens.

Anticoli S, Manfredi F, Chiozzini C, Arenaccio C, Olivetta E, Ferrantelli F, Capocefalo A, Falcone E, Ruggieri A, Federico M.

Biotechnol J. 2018 Apr;13(4):e1700443. doi: 10.1002/biot.201700443. Epub 2018 Mar 24.

PMID:
29274250
6.

The Multifaceted Functions of Exosomes in Health and Disease: An Overview.

Arenaccio C, Federico M.

Adv Exp Med Biol. 2017;998:3-19. doi: 10.1007/978-981-10-4397-0_1. Review.

PMID:
28936729
7.

Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation.

Di Bonito P, Chiozzini C, Arenaccio C, Anticoli S, Manfredi F, Olivetta E, Ferrantelli F, Falcone E, Ruggieri A, Federico M.

Int J Nanomedicine. 2017 Jun 23;12:4579-4591. doi: 10.2147/IJN.S131309. eCollection 2017.

8.

Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4+ T lymphocytes and reactivation of the HIV-1 reservoir.

Chiozzini C, Arenaccio C, Olivetta E, Anticoli S, Manfredi F, Ferrantelli F, d'Ettorre G, Schietroma I, Andreotti M, Federico M.

Arch Virol. 2017 Sep;162(9):2565-2577. doi: 10.1007/s00705-017-3391-4. Epub 2017 May 4.

PMID:
28474225
9.

The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant.

Manfredi F, di Bonito P, Ridolfi B, Anticoli S, Arenaccio C, Chiozzini C, Baz Morelli A, Federico M.

Vaccines (Basel). 2016 Nov 9;4(4). pii: E42.

10.

Incorporation of Heterologous Proteins in Engineered Exosomes.

Manfredi F, Di Bonito P, Arenaccio C, Anticoli S, Federico M.

Methods Mol Biol. 2016;1448:249-60. doi: 10.1007/978-1-4939-3753-0_18.

PMID:
27317186
11.

Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1.

Arenaccio C, Anticoli S, Manfredi F, Chiozzini C, Olivetta E, Federico M.

Retrovirology. 2015 Oct 26;12:87. doi: 10.1186/s12977-015-0216-y.

12.

The Contribution of Extracellular Nef to HIV-Induced Pathogenesis.

Olivetta E, Arenaccio C, Manfredi F, Anticoli S, Federico M.

Curr Drug Targets. 2016;17(1):46-53. Review.

PMID:
26424397
13.

The ADAR1 editing enzyme is encapsidated into HIV-1 virions.

Orecchini E, Federico M, Doria M, Arenaccio C, Giuliani E, Ciafrè SA, Michienzi A.

Virology. 2015 Nov;485:475-80. doi: 10.1016/j.virol.2015.07.027. Epub 2015 Sep 9.

14.

HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response.

Di Bonito P, Ridolfi B, Columba-Cabezas S, Giovannelli A, Chiozzini C, Manfredi F, Anticoli S, Arenaccio C, Federico M.

Viruses. 2015 Mar 9;7(3):1079-99. doi: 10.3390/v7031079.

15.

miR-146a controls CXCR4 expression in a pathway that involves PLZF and can be used to inhibit HIV-1 infection of CD4(+) T lymphocytes.

Quaranta MT, Olivetta E, Sanchez M, Spinello I, Paolillo R, Arenaccio C, Federico M, Labbaye C.

Virology. 2015 Apr;478:27-38. doi: 10.1016/j.virol.2015.01.016. Epub 2015 Feb 21.

16.

Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner.

Chiozzini C, Collacchi B, Nappi F, Bauer T, Arenaccio C, Tripiciano A, Longo O, Ensoli F, Cafaro A, Ensoli B, Federico M.

AIDS. 2014 Sep 24;28(15):2189-200. doi: 10.1097/QAD.0000000000000389.

PMID:
25313583
17.

Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism.

Arenaccio C, Chiozzini C, Columba-Cabezas S, Manfredi F, Affabris E, Baur A, Federico M.

J Virol. 2014 Oct;88(19):11529-39. doi: 10.1128/JVI.01712-14. Epub 2014 Jul 23.

18.

Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1.

Arenaccio C, Chiozzini C, Columba-Cabezas S, Manfredi F, Federico M.

Retrovirology. 2014 Jun 12;11:46. doi: 10.1186/1742-4690-11-46.

19.

HIV-1 Nef impairs key functional activities in human macrophages through CD36 downregulation.

Olivetta E, Tirelli V, Chiozzini C, Scazzocchio B, Romano I, Arenaccio C, Sanchez M.

PLoS One. 2014 Apr 4;9(4):e93699. doi: 10.1371/journal.pone.0093699. eCollection 2014.

Supplemental Content

Loading ...
Support Center